A Randomized Double-Blind Placebo-Controlled Study of the Efficacy Safety and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects with Autism Spectrum Disorders
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to compare the safety, benefits, and side effects of STX209 with placebo (inactive substance) in managing symptoms associated with Autism Spectrum Disorder.
Description
The purpose of this study is to compare the safety, benefits, and side effects of STX209 with placebo (inactive substance) in managing symptoms associated with Autism Spectrum Disorder.
Details
| Condition | Autism Spectrum Disorders |
|---|---|
| Age | 5years - 21years |
| Clinical Study Identifier | TX1632 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.